AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Serum paraoxonase/lactonase 3

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q15166

UPID:

PON3_HUMAN

Alternative names:

-

Alternative UPACC:

Q15166; A4D1H8; O75855; O76060; Q6IRU9; Q8IX97; Q9BZH9

Background:

Serum paraoxonase/lactonase 3, encoded by the gene with accession number Q15166, exhibits enzymatic activity towards a variety of substrates, including organophosphates and aromatic carboxylic acid esters. It is particularly effective in hydrolyzing lactones, such as those found in statin prodrugs like lovastatin, as well as aromatic lactones and certain ring lactones with aliphatic substituents.

Therapeutic significance:

Understanding the role of Serum paraoxonase/lactonase 3 could open doors to potential therapeutic strategies. Its ability to hydrolyze various lactones, including statin prodrugs, suggests a potential role in modulating drug efficacy and metabolism, which could be pivotal in the development of treatments for cardiovascular diseases and beyond.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.